CAJ | 학술논문

目的探讨硼替佐米联合CHOP方案治疗血管免疫母细胞性T细胞淋巴瘤(AITL)的有效性及安全性.方法 14例AITL患者应用硼替佐米(2mg/m2第1天)联合CHOP方案治疗,每21 d为1个疗程,对疗效、安全性及生存情况进行分析.结果 14例患者中初治12例,难治2例.12例患者治疗有效,其中完全缓解6例,部分缓解6例.14例患者3年预计生存率为55％,中位无进展生存时间9.4个月,3年预计无进展生存率为38％.Ⅲ～Ⅳ级中性粒细胞减少(6例)为最常见的血液学毒性;非血液学毒性均为Ⅰ～Ⅱ级,主要包括周围神经毒性(8例),恶心、呕吐(6例),腹泻(4例),感染(4例).结论硼替佐米联合CHOP方案治疗AITL可在不增加治疗相关不良反应的同时,提高治疗缓解率,改善预后,可用于AITL的诱导及挽救治疗.
목적 탐토붕체좌미연합CHOP방안치료혈관면역모세포성T세포림파류(AITL)적유효성급안전성.방법 14례AITL환자응용붕체좌미(2mg/m2제1천)연합CHOP방안치료,매21 d위1개료정,대료효、안전성급생존정황진행분석.결과 14례환자중초치12례,난치2례.12례환자치료유효,기중완전완해6례,부분완해6례.14례환자3년예계생존솔위55％,중위무진전생존시간9.4개월,3년예계무진전생존솔위38％.Ⅲ～Ⅳ급중성립세포감소(6례)위최상견적혈액학독성;비혈액학독성균위Ⅰ～Ⅱ급,주요포괄주위신경독성(8례),악심、구토(6례),복사(4례),감염(4례).결론 붕체좌미연합CHOP방안치료AITL가재불증가치료상관불량반응적동시,제고치료완해솔,개선예후,가용우AITL적유도급만구치료.
Objective To elucidate the curative effects and toxicity of bortezomib in combination with CHOP for patients with angioimmunoblastic T cell lymphoma (AITL).Methods The charts of 14 patients with AITL who received bortezomib 2 mg/m2 d1 plus CHOP regimen were reviewed.Results Among 14 patients including 12 initial and 2 refractory patients, 12 cases got remission (complete remission in 6 cases and partial remission in 6 cases).The anticipated 3-year overall survival rate was 55 ％.The median progression-free survival was 9.4 months.The anticipated 3-year progression-free survival rate was 38 ％.Grade Ⅲ-Ⅳ leucopenia was the most frequent hematological toxicity (6 cases).All of non-hematological toxicities were Ⅰ-Ⅱ grade including peripheral neurotoxicity (8 cases), nauseating and vomiting (6 cases), diarrhea (4 cases) and infection (4 cases).Conclusion The combination of bortezomib and CHOP is an effective and feasible regimen for AITL with acceptable toxicity.